Search results
Results from the WOW.Com Content Network
Inhaled nitric oxide is a gas that is inhaled. [1] It was initially described in 1987 as an "endothelial-derived relaxing factor" and has since been used to treat pulmonary disorders. [3] It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. [1] Inhaled nitric oxide selects only pulmonary smooth muscles.
Onset of effect is typically within half a minute, and the effect lasts for about a minute. [1] Nitrous oxide was discovered between 1772 and 1793 and used for anesthesia in 1844. [3] It is on the World Health Organization's List of Essential Medicines. [4] It often comes as a 50/50 mixture with oxygen. [1]
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Until the 1980s, nitric oxide, a product of fossil fuel combustion, was thought only to play a role the detrimental effects of air pollution on the respiratory tract. [17] In 1987, experiments with coronary arteries showed that nitric oxide was the long sought endothelium-derived relaxing factor.
Nitrous oxide (dinitrogen oxide or dinitrogen monoxide), commonly known as laughing gas, nitrous, or factitious air, among others, [4] is a chemical compound, an oxide of nitrogen with the formula N 2 O .
That can cause dangerous side effects in the long term, which is why doctors rarely prescribe oral corticosteroids for long-term asthma treatment. Another class of oral meds is called leukotriene ...
A STUDY FROM a team of Chinese and American researchers found that inhaled nitric oxide could potentially be a treatment for critically ill Covid-19 patients. It’s thought that nitric oxide’s ...
Inhaled nitric oxide (iNO) acts on vascular smooth muscle causing selective pulmonary vasodilation. This is ideal in the treatment of PPHN as it causes vasodilation within ventilated areas of the lung thus, decreasing the ventilation-perfusion mismatch and thereby, improves oxygenation.